S. Soliman
Matregenix,
United States
Keywords: biomaterials, soft tissue repair, guided bone regeneration
Summary:
The field of soft-tissue repair has seen little advancement in technology in recent decades, with current options such as hydrogels, sponges, and films lacking the necessary microscale architecture to promote tissue regeneration. Additionally, the use of biological materials like xenografts and allografts poses risks of disease transmission and has limited mechanical strength and shelf life. Synthetic biomaterials, like PLA, PLGA, and PCL, have been introduced to address these issues, but their degradation mechanisms cause inflammation and are difficult to predict. As a result, clinicians are forced to make compromises in clinical performance. Matregenix has developed MatriNova, a new platform technology for soft-tissue repair applications, utilizing nanofiber technology to create a programable, nonbiologic, antimicrobial, hybrid-scale fiber matrix similar to human extracellular matrix. MatriNova activates granulation tissue while maintaining tensile strength and flexibility, representing a new approach in the $20B soft-tissue repair market and shifting the market away from xenografts and allografts to synthetic tissue engineered scaffolds. The presentation will discuss the use of linear and branched l-valine and L-phenylalanine monomers processed into nanofibers via electrospinning, and present in vitro and in vivo data showing a limited inflammatory response in vivo and its use in a guided bone regeneration model.